alendronate / Generic mfg. - LARVOL DELTA

Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis. (PubMed, Eye (Lond)) - "This pharmacovigilance study identified associations between several systemic medications with reports of blepharitis, MGD, and chalazion. MGD and chalazion were overreported for finasteride and bortezomib, respectively, whereas all three conditions were overreported for dupilumab. These findings highlight systemic medications as often overlooked contributors to localised eyelid inflammation. Nonetheless, these drugs are known to reduce morbidity and mortality across many diseases. Therefore, while risks may not necessarily outweigh benefits to warrant changes in prescribing practices, clinicians should remain vigilant for such side effects, particularly in patients at higher risk, and to consider prophylactic measures when appropriate, such as educating patients about eyelid hygiene and counselling them to promptly report symptoms."

Adverse events • Journal • Real-world evidence • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

OsteoNAFLD: Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P4 | N=72 | Active, not recruiting | Sponsor: Aristotle University Of Thessaloniki | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Jul 2026

Enrollment closed • Trial primary completion date • Fibrosis • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatotic Liver Disease • Osteoporosis • Rheumatology • LEP

Clinical Characteristics and Management of Rare Metabolic Bone Diseases: An Audit of the Rare Metabolic Bone Disease Registry of India. (PubMed, Calcif Tissue Int) - "Different management strategies were used that included teriparatide, bisphosphonates (zoledronate or alendronate) with total contact casting, intralesional zoledronate, denosumab, calcium, active vitamin D, and recombinant human growth hormone. There were 29 RMBDs, and rickets/osteomalacia was the most prevalent subtype, tumor-induced osteomalacia followed by familial hypophosphatemic osteomalacia. Among the unclassified bone disorders, fragility fractures emerged as the most common presentation."

Journal • Review • Endocrine Disorders • Genetic Disorders • Musculoskeletal Diseases • Oncology • Orthopedics • Osteoporosis • Rare Diseases • Rheumatology • TGFB1

Inpatient rehabilitation fracture liaison service (FLS) improves outcomes for secondary prevention of hip fractures. (PubMed, Bone Rep) - "The prevalence of initiation and adherence to anti-osteoporotic treatments, including alendronate, risedronate, zoledronate, denosumab, romosozumab, and teriparatide, was compared between the rehabilitation FLS initiative patients and patients from other hospitals without FLS. The FLS in the inpatient rehabilitation setting was found to be highly effective in improving time to treatment initiation and adherence rates to prescribe anti-osteoporosis therapy. These findings demonstrate the role of FLS in addressing the osteoporosis treatment gap following fragility hip fracture."

Journal • Musculoskeletal Diseases • Oncology • Orthopedics • Osteoporosis • Rheumatology

Acute Pancreatitis Following Routine Screening Colonoscopy (ACG 2025) - "Her medications were omeprazole, letrozole, duloxetine, amlodipine, simvastatin and alendronate; all of which she has received for more than 3 years. Early recognition and vigilance allowed early triage and resulted in a favorable patient outcome. Inadvertent organ injury such as splenic laceration and injury, and less commonly acute pancreatitis are elements that gastroenterologists should consider in the patient with severe post-procedural pain following a colonoscopy among more common complications such as colonic perforation and post-polypectomy syndrome."

Cardiovascular • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hypertension • Hypotension • Metabolic Disorders • Pancreatitis

Hierarchically Reinforcing Hydrogel for Multidimensional Bone Homeostasis Modulation to Regenerate Osteoporotic Defect. (PubMed, Adv Healthc Mater) - "The simultaneous releasing of alendronate (ALN) further enhanced osteogenesis in BMSCs. Notably, osteogenically differentiated BMSCs also effectively suppressed the osteoclastogenesis of macrophages. Thus, this injectable hydrogel, integrating hierarchical stiffening and ALN delivery, presents a promising therapeutic strategy for restoring bone homeostasis to accelerate regeneration in osteoporotic defects."

Journal • Osteoporosis • RHOA

Does alendronate enhance survival rates in osteoporosis patients? A meta-analysis of randomized controlled trials. (PubMed, Sci Prog) - "The studies included in this analysis exhibited low heterogeneity, and no significant publication bias was detected.ConclusionsThe findings of this meta-analysis suggest that alendronate therapy does not enhance survival rates in osteoporosis patients, despite its effectiveness in reducing fracture risk. Therefore, the primary focus of osteoporosis treatment should remain on fracture prevention.PROSPERO registration number: CRD420251034567."

Clinical • Journal • Retrospective data • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Sodium alendronate doped chitosan based micro hybrid scaffold enhances in situ biomimetic mineralization and promotes endogenous bone regeneration. (PubMed, Int J Biol Macromol) - "Therefore, the prepared ALN doped composite scaffold can enhance the biomimetic mineralization ability of the scaffold and promote bone tissue regeneration at the defect site. In summary, this study provides a new method for biomimetic construction of porous scaffold materials, which enhances nHAP nucleation mineralization and bone repair by adding ALN, while promoting endogenous bone tissue regeneration."

Journal

Significant One-Year Bone Mineral Density Gains Following a Single Dose of Romosozumab: Insights from Two Case Studies (ENDO 2025) - "Here we report the one-year bone mineral density (BMD) gains following one dose of Romosozumab in two anabolic-naive patients.Case PresentationPatient 1 is a 76-year-old female diagnosed with osteoporosis in August 2023 and treated with Alendronate 70 mg daily for four months, followed by one dose of Romosozumab in April 2024, with no subsequent treatment. Between August 2023 and September 2024, she had statistically significant improvements in BMD at the lumbar spine (13.9%), right femur (7.9%), and left femur (9.6%).Patient 2 is a 67 year old female with osteoporosis treated with one dose of Romosozumab in January 2024 followed by one dose of Zoledronic acid in February 2024...Our patients' one-year BMD improvement after one dose of Romosozumab was similar to the one-year BMD improvement of clinical trial patients after twelve doses of Romosozumab. 2.There is a need for further research to determine whether shorter treatment courses could reduce fractures..."

Case study • Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Encapsulating Pt NCs with an AIE effect into a metal-organic framework as a novel fluorescence nanoprobe for discriminatively detecting bisphosphonate drugs. (PubMed, Anal Bioanal Chem) - "More importantly, our designed Pt NCs@ZIF-8-based nanoprobe also presents excellent discrimination capability toward four structurally similar BPs-Etidronate, Clodronate, Alendronate, and Risedronate, as confirmed by statistical techniques such as principal component analysis (PCA) and hierarchical clustering analysis (HCA). Finally, the proposed Pt NCs@ZIF-8 nanoprobe was successfully applied to quantify the labeled amount percentage of commercially available Sodium Risedronate and Sodium Alendronate tablets, achieving satisfactory limits of detection (LOD) spanning from 1.2 to 8.8 µM and excellent recovery ranging from 97.50% to 102.6%. This work not only provides a novel and convenient strategy for detecting and distinguishing BPs but also demonstrates the potential application of metal-organic frameworks encapsulating metal nanoclusters with AIE properties in pharmaceutical quality control."

Journal

Acute periapical abscesses may be a risk factor for medication-related osteonecrosis of the jaw. (PubMed, Am J Dent) - "Oral healthcare providers should be aware of the possible association between MRONJ and the higher occurrence of acute periapical abscesses. Enhanced oral hygiene and frequent dental visits are recommended to diagnose and treat dental pathoses promptly in MRONJ patients."

Journal • Diabetes • Metabolic Disorders

Holistic regulation of the diabetic osteo-microenvironment via NIR-II nanocarriers with dual NO/pH responsiveness for enhanced bone regeneration. (PubMed, Bioact Mater) - "The system integrates silver sulfide quantum dots (Ag2S QDs) and Sr2+ into mesoporous silica nanoparticles (MSNs), encapsulated with rhodamine/β-cyclodextrin and surface-modified with alendronate for bone-specific targeting...Concurrently, it boosts CD31, Runx2, and osteocalcin (OCN) expression levels at defect sites, indicating restored vascularization and osteogenesis. This strategy addresses the pathological triad of diabetic osteopathy-chronic inflammation, vascular insufficiency, and osteogenic impairment-providing a translatable nanotherapeutic paradigm for metabolic bone disorders."

IO biomarker • Journal • Diabetes • Inflammation • Orthopedics • BGLAP • CCR2 • CD31 • CD86 • MRC1 • PD-L1 • PECAM1 • RUNX2 • S100A4 • TGFB1 • TNFA • VEGFB

Safety Profile and Predictors of Adverse Events of Incadronate Disodium in Treating Breast Cancer Patients with Bone Metastases: A Retrospective Study. (PubMed, Breast Cancer (Dove Med Press)) - "Incadronate disodium demonstrates a favorable safety profile for treating bone metastases in breast cancer patients. Identified risk factors, such as prolonged treatment duration and lower hemoglobin levels, highlight the need for intensified dental health management and personalized treatment strategies."

Adverse events • Journal • Retrospective data • Breast Cancer • Endocrine Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor

Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021. (PubMed, Orthopedics) - "In line with national guidelines, claims for NSAIDs are increasing and claims for opioid pain medications and AOMs are decreasing. Claims for outpatient antibiotics are increasing, which is of significant concern, given renewed focus on antibiotic stewardship."

Journal • Medicare • Reimbursement • Review • US reimbursement • Orthopedics • Pain

Erythrocyte Membrane-Cloaked and Alendronate-Loaded Hollow Prussian Blue Nanoparticles for Synergistic Osteoporosis Therapy via Antioxidant and Targeted Delivery Mechanisms. (PubMed, ACS Omega) - "Transcription and protein expression analysis revealed downregulated NF-κB/MAPK signaling and osteoclast-specific markers after EAP treatment. This biomimetic nanodelivery system integrates ROS scavenging and targeted drug delivery, providing a potential strategy for OP therapy and other inflammatory bone disorders."

Journal • Inflammation • Orthopedics • Osteoporosis • Rheumatology

The use of alendronate to enhance transcranial transmission of focused ultrasound for successful ablations in brain. (PubMed, Ultrasonics) - "Alendronate therapy enhanced skull bone density distribution and thus ultrasound permeability, which has facilitated successful repeat MRgFUS. By visually analysing CT changes, healthcare professionals can better inform their decision-making regarding repeat surgeries. This method broadens the pool of patients with low SDR eligible for MRgFUS treatment and underscores the potential benefits of alendronate in improving treatment outcomes."

Journal • CNS Disorders • Dystonia • Essential Tremor • Movement Disorders • Parkinson's Disease

Identification of a novel TGFB1 variant in a patient with Camurati-Engelmann disease responsive to alendronate. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • TGFB1

Post-marketing Safety Surveillance of Drug-induced Dementia: Utilizing Signal Detection and Mendelian Randomization in Spontaneous Reports. (PubMed, Curr Med Chem) - "The adverse event data sourced from the FAERS database indicate that certain medications are associated with an increased risk of developing dementia, a finding corroborated by our Mendelian randomization analysis. Establishing a comprehensive monitoring and risk assessment program is crucial for identifying high-risk individuals and facilitating informed medication choices, thereby potentially reducing the incidence of dementia."

Journal • P4 data • Alzheimer's Disease • CNS Disorders • Dementia

Combined antiresorptive and new anabolic drug approach in osteogenesis imperfecta zebrafish models. (PubMed, JBMR Plus) - "In this study, dominant Chihuahua (Chi/+) and recessive p3h1-/- zebrafish OI models were treated for 2 mo either with the bisphosphonate alendronate (ALN) or with 4PBA or with a combination of the two...Finally, 4PBA and the combination of ALN and 4PBA reduced osteocyte apoptosis only in p3h1-/- . Our data demonstrated for the first time in vivo a differential effect of the combination of an antiresorptive and a new anabolic compound in dominant and recessive OI zebrafish models, stressing the importance of identifying the specific causative molecular defect to define the best treatment option."

Journal • Genetic Disorders

Retraction: Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells. (PubMed, PLoS One) - No abstract available

Journal • Lung Cancer • Oncology • Solid Tumor

Pretreatment with alendronate augments lipid A-induced IFN-β production via upregulation of cGAS expression. (PubMed, Pharmacol Rep) - "These results suggest that pretreatment with ALN augments lipid A-induced IFN-β production by J774.1 cells via the upregulation of cGAS expression."

IO biomarker • Journal • CASP1 • CGAS • IFNB1 • IRF5 • LMNB1 • STING • TLR4

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: University of California, Davis | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Cost-effectiveness of opportunistic osteoporosis screening using chest radiographs with deep learning in the United States. (PubMed, J Am Coll Radiol) - "This study underscores the cost-effectiveness and public health value of opportunistic, AI-driven screening osteoporosis screening using existing chest radiographs, demonstrating its potential to improve early detection and address unmet diagnostic needs in osteoporosis care."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Targeted delivery of liposomal senolytics to alleviate cellular senescence-induced bone loss. (PubMed, Fundam Res) - "Herein, we developed alendronate-functionalized liposomes carrying dasatinib and quercetin (Aln-Lipo-DQ), focusing mainly on senescence-associated osteoporosis induced by chemotherapy or radiotherapy. We also found a 2.91-fold increase in bone volume fraction in Aln-Lipo-DQ treated groups compared to the control in radiotherapy models. This selectively targeting bone and reducing senescent cells holds great promise for cancer treatment-related and senescence-associated bone disorders."

Journal • Oncology • Osteoporosis • Rheumatology

Based on metabolomics analysis, the method of strengthening spleen, tonifying kidney, and promoting blood circulation is used to treat rheumatoid arthritis with muscle wasting and osteoporosis (ChiCTR) - P1 | N=40 | Recruiting | Sponsor: Dongguan Traditional Chinese Medicine Hospital; Dongguan Traditional Chinese Medicine Hospital

New P1 trial • Immunology • Inflammatory Arthritis • Osteoporosis • Rheumatoid Arthritis • Rheumatology